Baker SD - Search Results

1

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD. Zimmerman EI, et al. Among authors: baker sd. Blood. 2013 Nov 21;122(22):3607-15. doi: 10.1182/blood-2013-07-513044. Epub 2013 Sep 17. Blood. 2013. PMID: 24046014 Free PMC article.

2

Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy.

Baker SD, Wadkins RM, Stewart CF, Beck WT, Danks MK. Baker SD, et al. Cytometry. 1995 Feb 1;19(2):134-45. doi: 10.1002/cyto.990190208. Cytometry. 1995. PMID: 7743894 Free article.

3

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.

Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. Stewart CF, et al. Among authors: baker sd. J Clin Oncol. 1994 Sep;12(9):1946-54. doi: 10.1200/JCO.1994.12.9.1946. J Clin Oncol. 1994. PMID: 8083716 Clinical Trial.

4

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF. Baker SD, et al. Cancer Chemother Pharmacol. 1996;37(3):195-202. doi: 10.1007/BF00688317. Cancer Chemother Pharmacol. 1996. PMID: 8529278

5

Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.

Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF. Furman WL, et al. Among authors: baker sd. J Clin Oncol. 1996 May;14(5):1504-11. doi: 10.1200/JCO.1996.14.5.1504. J Clin Oncol. 1996. PMID: 8622064 Clinical Trial.

6

Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.

Hu S, Niu H, Minkin P, Orwick S, Shimada A, Inaba H, Dahl GV, Rubnitz J, Baker SD. Hu S, et al. Among authors: baker sd. Mol Cancer Ther. 2008 May;7(5):1110-20. doi: 10.1158/1535-7163.MCT-07-2218. Mol Cancer Ther. 2008. PMID: 18483300

7

Interaction of imatinib with human organic ion carriers.

Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A. Hu S, et al. Among authors: baker sd. Clin Cancer Res. 2008 May 15;14(10):3141-8. doi: 10.1158/1078-0432.CCR-07-4913. Clin Cancer Res. 2008. PMID: 18483382 Free article.

8

Pharmacogenetic pathway analysis of docetaxel elimination.

Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. Baker SD, et al. Clin Pharmacol Ther. 2009 Feb;85(2):155-63. doi: 10.1038/clpt.2008.95. Epub 2008 May 28. Clin Pharmacol Ther. 2009. PMID: 18509327 Free PMC article.

9

Stability of sunitinib in oral suspension.

Navid F, Christensen R, Minkin P, Stewart CF, Furman WL, Baker S. Navid F, et al. Ann Pharmacother. 2008 Jul;42(7):962-6. doi: 10.1345/aph.1K654. Epub 2008 Jun 24. Ann Pharmacother. 2008. PMID: 18577759

10

Pharmacokinetic considerations for new targeted therapies.

Baker SD, Hu S. Baker SD, et al. Clin Pharmacol Ther. 2009 Feb;85(2):208-11. doi: 10.1038/clpt.2008.242. Epub 2008 Dec 17. Clin Pharmacol Ther. 2009. PMID: 19092780 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

268 results

Search Page